Lifevantage Corp (LFVN) — Titan Protect Analysis

LFVN

Lifevantage Corp

Consumer Defensive · ·

$9.97

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$112M

Total market value of the company

Trailing P/E

19.70

Reasonably valued

Forward P/E

19.41

Based on estimated future earnings — lower means cheaper

Rev Growth

-25.2%

Year-over-year revenue change

Profit Margin

2.9%

How much profit the company keeps from each dollar of revenue

ROE

17.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$7.00

-30% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About Lifevantage Corp

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Brig

https://www.lifevantage.com

Country: United States Employees: 232 Industry: Packaged Foods

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.498

Positive but modest risk-adjusted returns

Kelly Fraction

0.0334

Modest edge detected — smaller position warranted

Calmar Ratio

0.124

Drawdown risk outweighs the returns — higher risk profile

Annual Return

10.4%

Historical annualised return based on price data

Max Drawdown

-83.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.55

Less volatile than the market — more defensive

52W High

$15.00

34% below the year high

52W Low

$3.90

156% above the year low

Avg Volume

252,363

Average daily shares traded — higher means easier to buy and sell

Short Ratio

13.9

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

233.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$0.45

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

30.61

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

78.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

4.1%

Profit from core operations before interest and tax

Free Cash Flow

$2M

Positive — the business generates more cash than it spends

Revenue (TTM)

$195M

Total revenue over the last 12 months

Net Income

$6M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$9.00

Target Median

$7.00

Target Low

$5.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go